Sequence from project that provides insight on the role aberrant DNA methylation has in the abnormalities responsible for cancer cell growth, especially hematological malignancies such as leukemia, lymphoma, and multiple myeloma.

In this sequence, we begin with a view of “normal” DNA methylation, and then change to a view of hypermethylation underway.

Eventually, decitabine – a hypomethylating agent – can be seen moving into place and blocking DNA methyltransferase (DNMT), leading to the degradation of DNMT and eventual hypomethylation.

Targeting DNA methylation with DNA hypomethylating agents (HMAs) acts to reprogram tumor cells to a more normal-like state.

View animation >>

Tagged: aberrant DNA methylation patterns, abnormal methylation, biomedical communications, biotech, cancer, cedazuridine, cytidine deaminase, decitabine, DNA, DNA methylation, DNA methyltransferase inhibitors, DNMT degradation, epigenetic cancer therapy, gene expression, genetic mutations, genetics, hematological malignancies, histones, hybrid medical, hypermethylation, hypomethylating agents, hypomethylation, leukemia, medical animation, medical marketing, nucleosome, oncology, scientific animation